STAAR Surgical (NASDAQ:STAA) announces that the FDA has signed off on its planned study evaluating its EVO/EVO+ VISIAN Implantable Collamer Lens for myopia and its EVO/EVO+ Toric Implantable Collamer Lens for myopia with astigmatism.
The trial should launch next quarter.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.